1. Mayhew, AG, Moat, D, McDermott, MP, Eagle, M, Griggs, RC, King, WM et al.. Functional outcome measures in young, steroid-naïve boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2022;32 (6):460-467. doi: 10.1016/j.nmd.2022.02.012. PubMed PMID:35618576 .
  2. Guglieri, M, Bushby, K, McDermott, MP, Hart, KA, Tawil, R, Martens, WB et al.. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial. JAMA. 2022;327 (15):1456-1468. doi: 10.1001/jama.2022.4315. PubMed PMID:35381069 PubMed Central PMC8984930.
  3. Schiava, M, Amos, R, VanRuiten, H, McDermott, MP, Martens, WB, Gregory, S et al.. Clinical and Genetic Characteristics in Young, Glucocorticoid-Naive Boys With Duchenne Muscular Dystrophy. Neurology. 2022;98 (4):e390-e401. doi: 10.1212/WNL.0000000000013122. PubMed PMID:34857536 PubMed Central PMC8793104.
  4. Campbell, C, McColl, E, McDermott, MP, Martens, WB, Guglieri, M, Griggs, RC et al.. Health related quality of life in young, steroid-naïve boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2021;31 (11):1161-1168. doi: 10.1016/j.nmd.2021.06.001. PubMed PMID:34489153 .
  5. Thangarajh, M, Hendriksen, J, McDermott, MP, Martens, W, Hart, KA, Griggs, RC et al.. Relationships between DMD mutations and neurodevelopment in dystrophinopathy. Neurology. 2019;93 (17):e1597-e1604. doi: 10.1212/WNL.0000000000008363. PubMed PMID:31594858 PubMed Central PMC6946466.
  6. Kern, V, Wicklund, M, Haulman, A, McDermott, MP, Martens, WB, Griggs, RC et al.. Ankle bracing practices in ambulatory, corticosteroid-naive boys with Duchenne muscular dystrophy. Muscle Nerve. 2020;61 (1):52-57. doi: 10.1002/mus.26727. PubMed PMID:31588574 .
  7. Statland, JM, Moore, D, Wang, Y, Walsh, M, Mozaffar, T, Elman, L et al.. Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. Muscle Nerve. 2019;59 (2):201-207. doi: 10.1002/mus.26335. PubMed PMID:30192007 PubMed Central PMC6545236.
  8. Gang, Q, Bettencourt, C, Machado, PM, Brady, S, Holton, JL, Pittman, AM et al.. Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis. Neurobiol Aging. 2016;47 :218.e1-218.e9. doi: 10.1016/j.neurobiolaging.2016.07.024. PubMed PMID:27594680 PubMed Central PMC5082791.
  9. Pasnoor, M, He, J, Herbelin, L, Burns, TM, Nations, S, Bril, V et al.. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology. 2016;87 (1):57-64. doi: 10.1212/WNL.0000000000002795. PubMed PMID:27306628 PubMed Central PMC4932232.
  10. Pasternak, A, Sideridis, G, Fragala-Pinkham, M, Glanzman, AM, Montes, J, Dunaway, S et al.. Rasch analysis of the Pediatric Evaluation of Disability Inventory-computer adaptive test (PEDI-CAT) item bank for children and young adults with spinal muscular atrophy. Muscle Nerve. 2016;54 (6):1097-1107. doi: 10.1002/mus.25164. PubMed PMID:27121348 .
  11. Sansone, VA, Burge, J, McDermott, MP, Smith, PC, Herr, B, Tawil, R et al.. Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis. Neurology. 2016;86 (15):1408-1416. doi: 10.1212/WNL.0000000000002416. PubMed PMID:26865514 PubMed Central PMC4831040.
  12. Benatar, M, Mcdermott, MP, Sanders, DB, Wolfe, GI, Barohn, RJ, Nowak, RJ et al.. Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial. Muscle Nerve. 2016;53 (3):363-9. doi: 10.1002/mus.24769. PubMed PMID:26179124 PubMed Central PMC6038933.
  13. Montes, J, Glanzman, AM, Mazzone, ES, Martens, WB, Dunaway, S, Pasternak, A et al.. Spinal muscular atrophy functional composite score: A functional measure in spinal muscular atrophy. Muscle Nerve. 2015;52 (6):942-7. doi: 10.1002/mus.24670. PubMed PMID:25846132 .
  14. Gang, Q, Bettencourt, C, Machado, PM, Fox, Z, Brady, S, Healy, E et al.. The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis. Neurobiol Aging. 2015;36 (4):1766.e1-1766.e3. doi: 10.1016/j.neurobiolaging.2014.12.039. PubMed PMID:25670332 PubMed Central PMC4378665.
  15. Sengupta, M, Cheema, A, Kaminski, HJ, Kusner, LL, Muscle Study Group. Serum metabolomic response of myasthenia gravis patients to chronic prednisone treatment. PLoS One. 2014;9 (7):e102635. doi: 10.1371/journal.pone.0102635. PubMed PMID:25032816 PubMed Central PMC4102553.
  16. Kang, PB, Gooch, CL, McDermott, MP, Darras, BT, Finkel, RS, Yang, ML et al.. Reply: To PMID 23893312. Muscle Nerve. 2014;50 (3):458-9. doi: 10.1002/mus.24317. PubMed PMID:24935909 .
  17. Kang, PB, Gooch, CL, McDermott, MP, Darras, BT, Finkel, RS, Yang, ML et al.. The motor neuron response to SMN1 deficiency in spinal muscular atrophy. Muscle Nerve. 2014;49 (5):636-44. doi: 10.1002/mus.23967. PubMed PMID:23893312 PubMed Central PMC4090017.
  18. Sanders, DB, Burns, TM, Cutter, GR, Massey, JM, Juel, VC, Hobson-Webb, L et al.. Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?. Muscle Nerve. 2014;49 (4):483-6. doi: 10.1002/mus.23944. PubMed PMID:23835683 .
  19. Lewis, RA, McDermott, MP, Herrmann, DN, Hoke, A, Clawson, LL, Siskind, C et al.. High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol. 2013;70 (8):981-7. doi: 10.1001/jamaneurol.2013.3178. PubMed PMID:23797954 PubMed Central PMC3752369.
  20. Pasnoor, M, He, J, Herbelin, L, Dimachkie, M, Barohn, RJ, Muscle Study Group et al.. Phase II trial of methotrexate in myasthenia gravis. Ann N Y Acad Sci. 2012;1275 (1):23-8. doi: 10.1111/j.1749-6632.2012.06804.x. PubMed PMID:23278574 PubMed Central PMC3564221.
  21. Quijano-Roy, S, Avila-Smirnow, D, Carlier, RY, WB-MRI muscle study group. Whole body muscle MRI protocol: pattern recognition in early onset NM disorders. Neuromuscul Disord. 2012;22 Suppl 2 :S68-84. doi: 10.1016/j.nmd.2012.08.003. PubMed PMID:22980770 .
  22. Kaufmann, P, McDermott, MP, Darras, BT, Finkel, RS, Sproule, DM, Kang, PB et al.. Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology. 2012;79 (18):1889-97. doi: 10.1212/WNL.0b013e318271f7e4. PubMed PMID:23077013 PubMed Central PMC3525313.
  23. Rose, MR, Sadjadi, R, Weinman, J, Akhtar, T, Pandya, S, Kissel, JT et al.. Role of disease severity, illness perceptions, and mood on quality of life in muscle disease. Muscle Nerve. 2012;46 (3):351-9. doi: 10.1002/mus.23320. PubMed PMID:22907225 .
  24. Sadjadi, R, Vincent, KA, Carr, AJ, Walburn, J, Brooks, VL, Pandya, S et al.. Validation of the individualised neuromuscular quality of life for the USA with comparison of the impact of muscle disease on those living in USA versus UK. Health Qual Life Outcomes. 2011;9 :114. doi: 10.1186/1477-7525-9-114. PubMed PMID:22177525 PubMed Central PMC3295649.
  25. Glanzman, AM, McDermott, MP, Montes, J, Martens, WB, Flickinger, J, Riley, S et al.. Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). Pediatr Phys Ther. 2011;23 (4):322-6. doi: 10.1097/PEP.0b013e3182351f04. PubMed PMID:22090068 .
  26. Glanzman, AM, O'Hagen, JM, McDermott, MP, Martens, WB, Flickinger, J, Riley, S et al.. Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III. J Child Neurol. 2011;26 (12):1499-507. doi: 10.1177/0883073811420294. PubMed PMID:21940700 .
  27. Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 2011;70 (3):427-36. doi: 10.1002/ana.22477. PubMed PMID:21688301 PubMed Central PMC3170432.
  28. Kaufmann, P, McDermott, MP, Darras, BT, Finkel, R, Kang, P, Oskoui, M et al.. Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol. 2011;68 (6):779-86. doi: 10.1001/archneurol.2010.373. PubMed PMID:21320981 PubMed Central PMC3839315.
  29. Kaufmann, P, Annis, C, Griggs, RC, Muscle Study Group Executive Committee. The authorship lottery: an impediment to research collaboration?. Ann Neurol. 2010;68 (6):782-6. doi: 10.1002/ana.22232. PubMed PMID:21194150 .
  30. Sadjadi, R, Rose, MR, Muscle Study Group. What determines quality of life in inclusion body myositis?. J Neurol Neurosurg Psychiatry. 2010;81 (10):1164-6. doi: 10.1136/jnnp.2009.183863. PubMed PMID:20601666 .
  31. Montes, J, McDermott, MP, Martens, WB, Dunaway, S, Glanzman, AM, Riley, S et al.. Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy. Neurology. 2010;74 (10):833-8. doi: 10.1212/WNL.0b013e3181d3e308. PubMed PMID:20211907 PubMed Central PMC2839195.
  32. Jackson, CE, Gronseth, G, Rosenfeld, J, Barohn, RJ, Dubinsky, R, Simpson, CB et al.. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve. 2009;39 (2):137-43. doi: 10.1002/mus.21213. PubMed PMID:19145653 .
  33. Burns, TM, Conaway, MR, Cutter, GR, Sanders, DB, Muscle Study Group. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve. 2008;38 (6):1553-62. doi: 10.1002/mus.21185. PubMed PMID:19016543 .
  34. Mullins, LL, Carpentier, MY, Paul, RH, Sanders, DB, Muscle Study Group. Disease-specific measure of quality of life for myasthenia gravis. Muscle Nerve. 2008;38 (2):947-56. doi: 10.1002/mus.21016. PubMed PMID:18697209 .
  35. Burns, TM, Conaway, MR, Cutter, GR, Sanders, DB, Muscle Study Group. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve. 2008;38 (2):957-63. doi: 10.1002/mus.21053. PubMed PMID:18642357 .
  36. Vernino, S, Lindstrom, J, Hopkins, S, Wang, Z, Low, PA, Muscle Study Group et al.. Characterization of ganglionic acetylcholine receptor autoantibodies. J Neuroimmunol. 2008;197 (1):63-9. doi: 10.1016/j.jneuroim.2008.03.017. PubMed PMID:18485491 PubMed Central PMC2536520.
  37. Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008;71 (6):394-9. doi: 10.1212/01.wnl.0000312373.67493.7f. PubMed PMID:18434639 .
  38. Jackson, CE, Barohn, RJ, Gronseth, G, Pandya, S, Herbelin, L, Muscle Study Group et al.. Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve. 2008;37 (4):473-6. doi: 10.1002/mus.20958. PubMed PMID:18236463 .
  39. Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology. 2004;63 (4):718-20. doi: 10.1212/01.wnl.0000134675.98525.79. PubMed PMID:15326251 .
  40. Muscle Study Group. Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis. Neurology. 2001;57 (9):1566-70. doi: 10.1212/wnl.57.9.1566. PubMed PMID:11706093 .

Abstracts

  1. Burns TM, Conaway M, Sanders DB, Muscle Study Group. Correlation of quality-of-life with regional symptoms and signs in MG: Muscle Study Group CellCept trial experience. Ann NY Acad Sci 2008; 1132:369-370.
  2. Massey JM, Sanders DB, Saperstein DS, Barohn RJ, Meriggioli MN, Nations SP, Muscle Study Group. Comparison of single fiber EMG studies to outcome measures in a controlled study of mycophenolate mofetil in generalized MG. Ann NY Acad Sci 2008; 1132:377.